Blood thinner versus aspirin to prevent clots in certain blood disorders
Tests low-dose apixaban or rivaroxaban against aspirin in adults with JAK2-positive myeloproliferative neoplasms.
Key facts
- Who runs it
- Centre Hospitalier Regional Et Universitaire De Brest
- Where
- Angers, Argenteuil Cedex, Avignon, Bayonne, Béziers, Brest, Cesson Sevigne, Clermont-Ferrand, Créteil, Grenoble Cedex 9, La Roche Sur Yon Cedex 9, Le Chesnay Rocquencourt, Le Havre Cedex, Le Mans Cedex 9, Libourne, Limoges Cedex 1, Lyon, Marseille Cedex 05, Mont-De-Marsan Cedex, Montpellier Cedex 5, Morlaix, Nantes, ORLEANS, Paris, Périgueux, Perpignan Cedex, Pessac, Pringy Cedex, Quimper Cedex, Rennes, Rochefort Cedex, Roubaix, Rouen Cedex, Saint-Denis, Saint-Pierre Cedex, Saint-Priest-en-Jarez, Strasbourg, Tours, Vandoeuvre lès Nancy, Vannes, Villejuif Cedex, and Villeurbanne, FranceSee the 44 sites
- Registry title
- Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myeloproliferative neoplasms
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 1,008 people, planned
- Started
- 1 Aug 2024
- Expected to end
- 1 Jul 2029
- Type of study
- Interventional
- Record updated
- 11 July 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a JAK2V617F-positive blood cancer (polycythemia vera, essential thrombocythemia or prefibrotic myelofibrosis) who have a high risk of blood clots. It compares a low-dose blood thinner (apixaban/rivaroxaban) with aspirin.
- Age
- 18 years or older. People over 60 count as high-risk by age; people 18 or older with a clot history also count.
- Sex
- All sexes can join.
- Disease stage
- Polycythemia vera, essential thrombocythemia or prefibrotic myelofibrosis, diagnosed no more than 12 months before joining. The person must be high-risk for clots.
- Earlier treatment
- People who must take aspirin or a blood thinner for another reason cannot join. Use of a strong CYP3A4 inhibitor or inducer (like Ruxolitinib) is not allowed.
- Biomarker or test result
- JAK2V617F mutation, with an allele burden above 1%.
Main reasons for not taking part
- Cannot take aspirin or the blood thinner because of allergy or recent major bleeding
- High risk of bleeding, such as recent stomach, gut or brain bleeding
- Chronic liver disease or chronic hepatitis
- Kidney problems: creatinine below 30 ml/mn (Cockcroft and Gault formula)
- Life expectancy under 12 months, or PS above 2
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Patients with diagnosis of Polycythemia Vera or Essential Thrombocythemia or Prefibrotic myelofibrosis according to WHO or BSCH criteria (bone marrow biopsy not compulsory)
- Patients with JAK2V617F mutation (threshold allele burden > 1%)
- Patients considered as “high-risk” patients: - 1°) based on age (> 60-year-old) - 2°) based on thrombotic history (compatible with antithrombotic randomization) but aged ≥ 18-year-old
- Length of time from MPN diagnostic to inclusion will not exceed 12 months
Who cannot take part
- Formal indication of treatment with LDA or DOAC (thus precluding randomization)
- Concomitant use of a strong inhibitor or inducer of CYP3A4 (like Ruxolitinib)
- Contra-indication to aspirin or DOAC due to allergic situation or recent history of major bleeding
- Chronic liver disease or chronic hepatitis
- Patient considered at high-risk of bleeding: patients with current or recent major or clinically relevant non major bleeding gastrointestinal or cerebral bleedings
- Renal insufficiency with creatinine <30 ml/mn on Cockcroft and Gault Formula
- No appropriate contraception (estrogen contraception or no contraception) in women of childbearing age or breastfeeding woman
- PS>2 or life expectancy <12 months
- Inability to give informed consent
- Patients under curatorship/guardianship
- Planned pregnancy within 24 months
Where in France
- Centre Hospitalier Universitaire D'AngersAngers, FranceTaking people
- Centre Hospitalier Victor DupouyArgenteuil Cedex, FranceTaking people
- Centre Hospitalier d'AvignonAvignon, FranceTaking people
- Centre Hospitalier de la Cote BasqueBayonne, FranceTaking people
- Centre Hospitalier de BéziersBéziers, FranceTaking people
- Centre Hospitalier Régional et Universitaire de BrestBrest, FranceTaking people
- Hopital Prive SevigneCesson Sevigne, FranceTaking people
- CHU d'EstaingClermont-Ferrand, FranceTaking people
- Hôpital Henri Mondor, 1 rue Gustave Eiffel,Créteil, FranceTaking people
- Centre Hospitalier Universitaire Grenoble AlpesGrenoble Cedex 9, FranceTaking people
- Centre Hospitalier Departemental VendeeLa Roche Sur Yon Cedex 9, FranceTaking people
- Centre Hospitalier De VersaillesLe Chesnay Rocquencourt, FranceTaking people
- Groupe Hospitalier Du HavreLe Havre Cedex, FranceTaking people
- Centre Hospitalier Le MansLe Mans Cedex 9, FranceTaking people
- Centre Hospitalier De Libourne Robert BoulinLibourne, FranceTaking people
- Centre Hospitalier Et Universitaire De LimogesLimoges Cedex 1, FranceTaking people
- Centre Leon BerardLyon, FranceTaking people
- Centre Hospitalier Regional De MarseilleMarseille Cedex 05, FranceTaking people
- Centre Hospitalier Intercommunal De Mont De Marsan Et Du Pays Des SourcesMont-De-Marsan Cedex, FranceTaking people
- Centre Hospitalier Universitaire De MontpellierMontpellier Cedex 5, FranceTaking people
- Centre Hospitalier des Pays de MorlaixMorlaix, FranceTaking people
- Centre Hospitalier Universitaire de NantesNantes, FranceTaking people
- Hôpital Privé du ConfluentNantes, FranceTaking people
- Centre Hospitalier Universitaire d'OrléansORLEANS, FranceTaking people
- Hopital Cochin Saint Vincent De PaulParis, FranceTaking people
- Hopital Saint LouisParis, FranceTaking people
- Centre Hospitalier de PerigueuxPérigueux, FranceTaking people
- Centre Hospitalier De PerpignanPerpignan Cedex, FranceTaking people
- Centre Hospitalier Universitaire de BordeauxPessac, FranceTaking people
- Centre Hospitalier Annecy GenevoisPringy Cedex, FranceTaking people
- Centre Hospitalier Intercommunal De CornouailleQuimper Cedex, FranceTaking people
- Centre Hospitalier Universitaire de RennesRennes, FranceTaking people
- Centre Hospitalier De RochefortRochefort Cedex, FranceTaking people
- Centre hospitalier de RoubaixRoubaix, FranceTaking people
- Centre Henri BecquerelRouen Cedex, FranceTaking people
- Centre Hospitalier Universitaire De La ReunionSaint-Denis, FranceTaking people
- Centre Hospitalier Universitaire de la Réunion - Site SudSaint-Pierre Cedex, FranceTaking people
- Institut de Cancérologie Lucien NeuwirthSaint-Priest-en-Jarez, FranceTaking people
- Clinique Sainte AnneStrasbourg, FranceTaking people
- Centre Hospitalier Régional Universitaire de ToursTours, FranceTaking people
- CHU Nancy - Hôpital BraboisVandoeuvre lès Nancy, FranceTaking people
- Centre Hospitalier Bretagne AtlantiqueVannes, FranceTaking people
- Hopital Paul BrousseVillejuif Cedex, FranceTaking people
- Médipôle Hôpital Mutualiste VilleurbanneVilleurbanne, FranceTaking people
About the trial
What the trial wants to find out
To demonstrate that low-dose DOAC is more effective than LDA in the primary prevention of arterial or venous thrombosis in JAK2V617F-positive high-risk MPN patients
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myeloproliferative neoplasms
- Plain-language title
- Blood thinner versus aspirin to prevent clots in certain blood disordersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 11 July 2025